Glutaminase enzyme types as personalized markers for prostate cancer
Glutaminase I isoforms as personalized biomarkers of prostate cancer
This project looks at two forms of a cancer enzyme called glutaminase to help predict how prostate cancer will respond to hormone treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Duke University NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project ID | NIH-11259539 on NIH RePORTER |
What this research studies
If you have prostate cancer, researchers will compare two forms of the glutaminase enzyme (KGA and GAC) in tumor tissue to see which form links with response to hormone therapy. They will study biopsy and archived tumor samples and run lab tests to measure which isoform a tumor makes and whether that matches past treatment outcomes. The team will look at early, hormone-sensitive cancers versus late, therapy-resistant cancers to map patterns and differences between patients. The goal is to turn those findings into a test that helps doctors choose the best hormonal treatment for each patient.
Who could benefit from this research
Good fit: Men with prostate cancer who have available tumor biopsies or archived tumor tissue and who are considering or undergoing hormonal therapy are the most relevant candidates.
Not a fit: Patients without prostate cancer, or those whose tumors do not express these glutaminase forms or whose treatment decisions are not influenced by biomarker information, may not benefit directly.
Why it matters
Potential benefit: If successful, this could help doctors predict which patients will respond to hormonal therapy and tailor treatments to each tumor's enzyme pattern.
How similar studies have performed: Some prior work targeting glutaminase in cancer models has shown promise, but using GLS1 isoform patterns as a clinical marker for prostate cancer is relatively new.
Where this research is happening
Durham, United States
- Duke University — Durham, United States (Active)
Researchers
- Principal investigator: Huang, Jiaoti — Duke University
- Study coordinator: Huang, Jiaoti
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.